

**SCIENTIFIC PANEL ON  
Nutrition, Novel Foods and Food Allergens**  
166<sup>th</sup> NDA Panel Plenary meeting



04 March 2026

09:00 – 18:00

AGENDA

**Location:** Teleconference

**Chair:** Dominique Turck

No.	Item
1	<b>Welcome and Apologies for absence</b>
2	<b>Adoption of the agenda</b>
3	<b>Declarations of interest</b>
4	<b>Agreement on the minutes of the 165th Plenary meeting held on 28-29 January 2026</b>
5	<b>Scientific outputs submitted for discussion/possible adoption</b>
5.1	<b>Draft opinion on 3'-Sialyllactose (3'-SL) sodium salt (<a href="#">EFSA-Q-2024-00002</a>, NF 2023-16923) Applicant: <i>Inbiose N.V.</i></b>
5.2	<b>Draft opinion on carbon dioxide extract from <i>Cannabis sativa</i> L. (NF 2021/2397 (<a href="#">EFSA-Q-2021-00218</a>, NF 2021/2397) Applicant: <i>Charlotte's Web</i></b>
5.3	<b>Draft opinion on L-alpha-glycerolphosphorylcholine (L-alpha-GPC) from soya phospholipids (lecithin) (<a href="#">EFSA-Q-2023-00492</a>, NF-2023-12770) Applicant: <i>Chemi S.p.A</i></b>
5.4	<b>Draft opinion on beta-Nicotinamide mononucleotide (beta-NMN) (<a href="#">EFSA-Q-2023-00552</a>, NF 2023-17850) Applicant: <i>Effepharm (Shanghai) Ltd</i></b>
6	<b>Other scientific topics for information/discussion/endorsement</b>
7	<b>Feedback from the Scientific Committee/ Scientific Panels/EFSA/ EC</b>
8	<b>Any other business</b>
18:00	End of the meeting